The FDA has approved the first-ever mRNA flu vaccine, marking a potential shift in how the U.S. approaches seasonal influenza. Moderna's mFLUSIVA (mRNA-1010) won full approval for adults ages 50-64 and accelerated approval for those 65 and older, with a required postmarketing study to confirm effectiveness in seniors.

Vital Signs

• 26.6% relative efficacy versus standard flu shots in the pivotal Fluent trial
• 27.4% efficacy in 19,000+ adults aged 65 and...